Viz.ai, Hyperfine to Offer New MR Imaging and Workflow Paradigm

Viz.ai and Hyperfine Inc. are teaming up to expedite diagnostic and imaging services for clinicians and patients.

This partnership is designed to further decrease the time from admission to treatment by expediting clinician access to magnetic resonance imaging (MRI) and increasing access to time-critical diagnostics in the acute and post-acute care phase.

“The partnership between Hyperfine and Viz.ai will help us integrate two breakthrough technologies that already enable us to better assess patients in a time-critical fashion and make timely decisions that will ultimately save more lives and improve outcomes,” said Shahid M. Nimjee, M.D., Ph.D., associate professor of Neurosurgery, surgical director of the Comprehensive Stroke Center, The Ohio State University Medical Center. “By combining these two proven technologies, we hope to further expedite care, when every second matters and transportation presents additional risk.”

Viz.ai’s mission is to fundamentally improve healthcare delivery through intelligent software that promises to reduce time to treatment, improve access to care, and increase the speed of medical innovation. Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat. In stroke, speed matters, as delays in care can lead to severe morbidity and mortality.
 
Hyperfine’s Swoop—a magnetic resonance imaging system capable of providing neuroimaging at the point of care—expands patient access to MRI by bringing imaging to the bedside. The Swoop system allows physicians to make quick and informed clinical decisions for patients, eliminating hours of wait and transport time and reducing the potential for adverse events associated with transporting critically ill patients.
 
“Partnering with Hyperfine to enhance the clinical workflow and expedite the clinical team’s access to imaging has the potential to result in better patient outcomes where time is critical in the ER and ICU,” said Jayme Strauss, chief clinical officer at Viz.ai. “With this partnership, we will be able to combine Viz’s intelligent care coordination platform and leading image viewer with the Hyperfine Swoop Portable MR Imaging System™.”
 
“This new partnership between Viz.ai and Hyperfine has the potential to enable healthcare providers to reduce neuroimaging wait times, streamline their clinical workflow coordination, and improve patient care from door to discharge,” said Scott Huennekens, Hyperfine’s board chair.
 
Hyperfine Inc. created Swoop, the first FDA-cleared portable MRI system. Hyperfine designed Swoop to enable rapid diagnosis and treatment of all patients regardless of income, resources, or location, pushing the boundaries of conventional imaging technology and expanding patient access to timely care. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength, allowing clinicians to quickly scan, diagnose and treat patients in various point-of-care clinical settings. Swoop can be wheeled directly to the patient’s bedside, plugged into a standard electrical wall outlet, and controlled by a tablet. Designed as a complementary system to conventional MRIs at a fraction of the cost, Swoop captures images in minutes, providing critical decision-making capabilities across a variety of clinical settings. 

Viz.ai, located in San Francisco, Tel Aviv, Portugal, and Amsterdam, pioneered the use of AI algorithms and machine learning to increase the speed of diagnosis and care for a variety of acute and emergent diseases across hospitals and health systems. The Viz Platform is a transformative, intelligent care coordination solution that unifies synchronized care collaboration, high fidelity mobile image viewing, automated workflows and improved visibility at decision-making moments. Viz.ai’s comprehensive neurovascular and vascular AI platform is clinically proven to save time and improve patient outcomes and access to care and is used in more than 1,000 hospitals in the United States, Europe, Middle East, and Africa.